An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers

BACKGROUND: CD3-based bispecific T cell engagers (bsTCEs) are one of the most promising bispecific antibodies for effective cancer treatments. To elicit target-specific T cell-mediated cytotoxicity, these bsTCEs contain at least one binding unit directed against a tumor antigen and another binding u...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ninghai, Patel, Harshal, Schneider, Irene C, Kai, Xin, Varshney, Avanish K, Zhou, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Bispecific Antibody CMC
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220303/
https://www.ncbi.nlm.nih.gov/pubmed/34169228
http://dx.doi.org/10.1093/abt/tbab009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220303/
https://www.ncbi.nlm.nih.gov/pubmed/34169228
http://dx.doi.org/10.1093/abt/tbab009

Ejemplares similares